Cargando…

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients. Isatuximab (10 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Usmani, Saad Z., Karanes, Chatchada, Bensinger, William I., D’Souza, Anita, Raje, Noopur, Tuchman, Sascha A., Sborov, Douglas, Laubach, Jacob P., Bianchi, Giada, Kanagavel, Dheepak, Saleem, Rao, Dubin, Franck, Campana, Frank, Richardson, Paul G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632673/ https://www.ncbi.nlm.nih.gov/pubmed/34050260 http://dx.doi.org/10.1038/s41375-021-01262-w

Ejemplares similares

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
por: Moreau, Philippe, et al.
Publicado: (2023)

Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
por: Shen, Fei, et al.
Publicado: (2022)

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS
por: Quach, H., et al.
Publicado: (2022)

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients
por: Fau, Jean‐Baptiste, et al.
Publicado: (2020)

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2019)

Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma
por: Idogun, Precious O, et al.
Publicado: (2022)

Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma
por: Ueno, Toshiyuki, et al.
Publicado: (2021)

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
por: Carlo‐Stella, Carmelo, et al.
Publicado: (2022)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2022)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
por: Zhu, Chen, et al.
Publicado: (2020)

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study
por: Boissel, Nicolas, et al.
Publicado: (2022)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
por: Yee, Andrew J, et al.
Publicado: (2012)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
por: Mikhael, Joseph, et al.
Publicado: (2020)

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
por: Djebbari, Faouzi, et al.
Publicado: (2022)

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
por: Lesokhin, Alexander, et al.
Publicado: (2023)

(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas
por: Herrero Alvarez, Natalia, et al.
Publicado: (2023)

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation
por: Malki, Monzr M. Al, et al.
Publicado: (2019)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2020)

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone
por: Thai, Hoai‐Thu, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis
por: Spicka, Ivan, et al.
Publicado: (2022)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
por: Bernstein, Zachary S., et al.
Publicado: (2022)

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
por: Richardson, Paul G, et al.
Publicado: (2012)

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
por: Sunami, Kazutaka, et al.
Publicado: (2020)

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
por: Koiwai, Kimiko, et al.
Publicado: (2021)

Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
por: Sun, Haibo, et al.
Publicado: (2021)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_opmm07ildimscs2hloostj600u